Program
UTAA07
A development code. Also written as “UTAA07 injection”.
Its studies are led by PersonGen BioTherapeutics (Suzhou).
Furthest: early phase 1, since Dec 16, 20251 company-led study, 1 open or runningNext primary completion: Dec 31, 2027 (early phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) | 11 open or running | early phase 1since Dec 16, 2025 | Dec 16, 2025 | Dec 31, 2027early phase 1 · NCT07338604 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2025First study: early phase 1 study in Hematolymphoid MalignanciesFirst studyNCT07338604 · 15 planned · China
Ahead
- Dec 31, 2027Primary completion: early phase 1 study in Hematolymphoid MalignanciesNCT07338604
TargetBeta
CD7 →read by rule
“UTAA07 Injection is a chimeric antigen receptor (CAR)-engineered γδ T-cell product that targets the CD7 antigen expressed on the surface of tumor cells.”study text, by rule · the study
Other programs on CD7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Autologous Anti-CD7 CAR T Cells PA3-17rule | PersonGen BioTherapeutics (Suzhou) | phase 2 | 6 |
| Anti-CD7 CAR-T Cells RD13-02rule | nanjing-bioheng-biotech-co-ltd | early phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07338604Hematolymphoid Malignancies · China | Early 1 | Recruiting | Dec 31, 2027 | 15 |
How it is read
Names in the registry
- “UTAA07 injection”, 1 entry
Codes read as this program: UTAA07.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.